On November 9, 2026, Delix Therapeutics (Delix), a clinical-stage neuroscience company pioneering the discovery and development of neuroplastogens, announced the closing of an oversubscribed $100 million Series C financing. The round was led by Johnson & Johnson Innovation – JJDC, Inc., the corporate venture capital organization of Johnson & Johnson, and SV Health Investors’ Dementia Discovery Fund, with participation from existing investors including RA Capital, UC Investments, Artis Ventures, OMX Ventures, Dolby Family Ventures, and Bail Capital, as well as new investors, including Adage Capital Management, Hamilton Square Partners Management, Vestal Point Capital, and YK Bioventures, among others. Wilson Sonsini Goodrich & Rosati advised Delix on the intellectual property matters related to the transaction.

The financing will allow Delix to advance Zalsupindole through Phase IIb proof of concept in recurrent major depressive disorder while supporting continued development of the company’s broader neuroplastogen pipeline, including additional development candidates and expansion of its neurodegeneration program.

The Wilson Sonsini team that advised Delix on the IP matters related to the transaction included Deborah Smith, Michael Hostetler, Yingchun Ni, and Michael Wormald.

For more information, please see Delix’s news release. Additional information can be found on Fierce Biotech and Bloomberg.